Centocor seeks paediatric ulcerative colitis indication for Remicade
This article was originally published in Scrip
Executive Summary
Centocor Ortho Biotech is looking to expand the label for its anti-TNF Remicade (infliximab) to include moderately to severely active ulcerative colitis in paediatric patients who do not adequately respond to conventional therapies. The product is already approved for treating adults with the same condition.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.